|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||63.31 - 64.68|
|52 Week Range||25.38 - 87.65|
|PE Ratio (TTM)||9.57|
|Forward Dividend & Yield||3.03 (4.69%)|
|1y Target Est||N/A|
Private equity group Nordic Capital has dropped out of the race to buy the European generics business of French pharmaceutical firm Sanofi because “price expectation is very high”, according to two people ...
But what is clear is that in the not too distant future, PCSK9 inhibitors will be priced in a way that will be palatable to payers thereby making this class of important drugs available to those whose lives can be saved or prolonged by them.
How far off is Sanofi (ENXTPA:SAN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly pricedRead More...
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Drugmakers tried just about every move under the sun to nurture sales of its products -- pharmacy coupons for patients, exclusive deals with insurers, even selling a medicine’s patent to a Native American ...
Regeneron CEO Leonard Schleifer says the biotech firm will lower the price of Praluent so long as insurers make it easier to claim a reimbursement.
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.
The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients....
A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine. The drug, Praluent, also led to fewer deaths among high-risk patients, which could be the strongest argument for insurers to finally remove barriers that have severely constrained sales and frustrated physicians trying to get the medicine to patients. Insurers have balked at paying for Praluent and a rival Amgen drug, which dramatically lower "bad" LDL cholesterol but carry list prices of more than $14,000 a year before discounts, over fear of the cost of use over many years by millions of patients.
Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients. Since the approvals in 2015 of Praluent and a similar rival biotech drug from Amgen Inc, insurers and pharmacy benefit managers have been rejecting some 70 percent of prescriptions written, severely holding back sales and frustrating doctors and at-risk heart patients.
New data in hand, Regeneron and Sanofi plan to offer insurers new rebates and discounts. Can they end the Mexican standoff that has prevented even the neediest patients from getting a promising drug?
Sanofi and Regeneron achieved a modest victory for their cholesterol lowering drug Praluent, but it is unlikely the trial will dramatically improve a challenging landscape.
Regeneron Pharmaceuticals Inc. and Sanofi are taking the unprecedented step of cutting the price of their $14,000-a-year heart drug Praluent and narrowing its use to high-risk patients shown to benefit ...
A cholesterol drug made by Regeneron and Sanofi was shown to reduce the risk of cardiac events like heart attack and stroke, reports CNBC's Meg Tirrell with the latest results.